70 likes | 187 Vues
Learn about the benefits and risks of using MTP in osteosarcoma treatment, including flu-like symptoms management and survival outcomes from a 20-year study.
E N D
Benefits and Risks Eugenie Kleinerman, MD Professor and Head, Division of PediatricsMD Anderson Cancer Center 2074.01
Safety Side effects reflect activity of MTP Flu-like symptoms; treated with acetaminophen No increase in chemo toxicity Optimal biologic dose < Maximum tolerated dose Compliance rather than safety concerns 2078.01
Consistency of Efficacy Results: ITT N Events N Events MTP 338 107 MTP 338 63 No MTP 340 133 No MTP 340 85 2519.01
Survival: 2006 ITT MTP No MTP 2521.01
Summary • Over 20 years of data with MTP in young people • Phase 3 trial designed to determine efficacy • Phase 3 study is largest US trial in osteosarcoma • No new agents for osteosarcoma since MTX approved • Survival data translate into 50 more cures per year 2522.01